EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway

Yunsheng Xu iD, Yanan Li iD, Zhiling Cheng iD, Chenyue Shao iD, Xinru Zhao iD, Yuming Liu iD, Xiangbo Gou iD, Congxin Li iD

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s585989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Yunsheng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Doxorubicin, Sodium-Hydrogen Exchanger 1, Cardiotoxicity, Guanidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinSodium-Hydrogen Exchanger 1CardiotoxicityGuanidinesBenzamidesAnimalsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMicePhosphatidylinositol 3-KinasesMaleSignal TransductionApoptosisDose-Response Relationship, DrugRatsMyocytes, CardiacStructure-Activity RelationshipMolecular Structure

Stichwörter der Autor:innen

NHE1 inhibitorPI3K/Akt/mTORapoptosisautophagycardiotoxicitydoxorubicin

Substanzen

DoxorubicinTOR Serine-Threonine KinasesSodium-Hydrogen Exchanger 1Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesGuanidinesBenzamidesSlc9a1 protein, mousemTOR protein, mouse

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, People's Republic of China.
  • Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, People's Republic of China.
  • College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.

ORCID-Profile: Yunsheng Xu, Yanan Li, Zhiling Cheng, Chenyue Shao, Xinru Zhao, Yuming Liu, Xiangbo Gou, Congxin Li

Zitieren

APA

Xu, Y., Li, Y., Cheng, Z., Shao, C., Zhao, X., Liu, Y., Gou, X., & Li, C. (2026). GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s585989

Vancouver

Xu Y, Li Y, Cheng Z, Shao C, Zhao X, Liu Y, et al. GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s585989

BibTeX
@article{Xu2026,
  author = {Xu, Yunsheng and Li, Yanan and Cheng, Zhiling and Shao, Chenyue and Zhao, Xinru and Liu, Yuming and Gou, Xiangbo and Li, Congxin},
  title = {GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s585989}
}
Kostenlos starten →